Deal Snapshot
Philip Morris Closes Acquisition of Fertin Pharma for an Enterprise Value of DKK 5.1bn
Friday 17 September 2021

US-based tobacco company Philip Morris International Inc. (NYSE: PM) (PMI) has closed the acquisition of Danish Fertin Pharma A/S, a developer and manufacturer of pharmaceutical and well-being products based on oral and intra-oral delivery systems, for an enterprise value of DKK 5.1bn (USD 820m), the company said.

The acquisition advances PMI's goal to become a majority smoke-free business by 2025 and creates growth opportunities beyond nicotine. The acquisition of Fertin Pharma will enhance PMI's smoke-free portfolio, notably in modern oral, and accelerating progress beyond nicotine.

Date Published: 17/09/2021